We are live on ! Find out more
EUCRW

Eucrates Biomedical Acquisition Corp. Warrant
EUCRW

Delisted

EUCRW was delisted on the 26th of April, 2023.

Back to rankings

24 hedge funds and large institutions have $1.07M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less capital invested

Capital invested by funds: $1.09M → $1.07M (-$21.3K)

8% less funds holding

Funds holding: 26 → 24 (-2)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
6
Closed
2
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
+$7.05K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.96K
2
OMC
Old Mission Capital
Illinois
-$1K
3
PC
Periscope Capital
Ontario, Canada
-$690
4
CH
CVI Holdings
Delaware
-$485
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$117
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$668K – – –
RCM
2
Radcliffe Capital Management
Pennsylvania
$334K – – –
DM
3
Deerfield Management
New York
$13K – – –
6CM
4
683 Capital Management
New York
$8K – – –
BlackRock
5
BlackRock
New York
$6K -$2.96K -46,843 -16%
ACM
6
Altium Capital Management
New York
$5K – – –
CAC
7
Cowen and Company
New York
$5K – – –
GPCM
8
Granite Point Capital Management
Massachusetts
$5K – – –
MF
9
Magnetar Financial
Illinois
$5K +$7.05K +111,332 +576%
Goldman Sachs
10
Goldman Sachs
New York
$4K -$13 -200 -0.1%
AI
11
Arena Investors
New York
$3.72K – – –
CH
12
CVI Holdings
Delaware
$3K -$485 -7,664 -7%
AA
13
AQR Arbitrage
Connecticut
$2K – – –
HM
14
HealthCor Management
New York
$2K – – –
KCM
15
Kingdon Capital Management
New York
$2K – – –
PC
16
Periscope Capital
Ontario, Canada
$1K -$690 -10,900 -42%
Hudson Bay Capital Management
17
Hudson Bay Capital Management
Connecticut
$1K -$117 -1,846 -7%
Jane Street
18
Jane Street
New York
$1K -$54 -857 -3%
RCM
19
Rivernorth Capital Management
Florida
$1K – – –
SC
20
Sculptor Capital
New York
$1K – – –
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$1K – – –
OMC
22
Old Mission Capital
Illinois
– -$1K -17,392 Closed

EUCRW Hedge Fund Activity: Q3 2022 in Review

24 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q3 2022, worth a combined $1.07M — down 1.9% from $1.09M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EUCRW and 0 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 1 added.

The largest buyer was Magnetar Financial, adding an estimated $7.05K. The largest seller was BlackRock, cutting an estimated $2.96K.

  • 24 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q3 2022, down from 26 in Q2 2022.
  • Funds reported $1.07M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q3 2022, down 1.9% quarter-over-quarter.
  • 0 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q3 2022 and 2 closed out, a net change of -2 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q3 2022 was Magnetar Financial, an estimated $7.05K added.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q3 2022 was BlackRock, an estimated $2.96K sold.

Based on aggregated 13F filings for Q3 2022.